Kıdney Cancer Treatment Methods

Table of Contents

Kıdney Cancer Treatment Methods

Kidney cancer is a vascular tumor, so anti-hypertensive drugs to suppress vascular hyperactivity are needed. It is important to avoid drugs such as aspirin, indomethacin, and intra-articular drugs that act on platelet dysfunction. It is good to coagulate some anti-blood clotting drugs and reduce their doses by assessing postoperative bleeding tendency. Because kidney cancer is highly vascular, blood clots can form after plasma surgery. Cancer patients can develop typha due to malnutrition, so nutrition should be provided according to patient status and hypermetabolism with glucose, lipid solution, protein, and vitamin supply.

The treatment of advanced renal cell carcinoma that has spread to a remote site and is impossible to remove by surgery, radiotherapy has demonstrated good results. In kidney cancer treatment, plasma surgery is used when the tumor cannot be removed by removing the patient’s kidney or damaging the patient’s health, especially in elderly patients with other diseases. 

Large amounts of blood are lost during surgery using plasma. However, because plasma surgery is expensive and requires human expertise, Da Vinci Pstubot coplerobotic partial ablation technology has been developed as a less expensive and minimally invasive alternative to treat kidney cancer with good effectiveness. Symptoms such as fever and pain should be controlled with symptom control. Problems such as urinating, eating, malaise, constipation, and thirst should be addressed with appropriate medical treatment.

Kidney cancer treatment methods. In addition to surgery, treatment options for renal cell carcinoma are active surveillance, percutaneous ablation, radiation therapy, hormone therapy, targeted therapy, or immunotherapy.

Frequently Asked Questıons

Why are the new oral chemotherapy agents for kıdney cancer generally well tolerated and effectıve regardless of a patıent's chronıc renal faılure, and what role mıght blood dıalysis play ın theır treatment strategy?

Because of their specific pharmacokinetics, the chemotherapy agents for kidney cancer are generally well tolerated by the majority of the oncological patients. Using the new oral kidney cancer chemotherapeutic agents such as Sunitinib, Sorafenib, Temsirolimus, studies have shown that anti-tumor efficacy is not related to the patient’s chronic renal failure. Blood dialysis has no clear indications in renal cancer and would be potentially effective if it might prove its anti-tumor activity. This is the case with Interleukin-2.

What are the sıde effects?

The side effects or, better said, toxic effects observed as a result of the kidney cancer therapy are variable ranging from patient to patient. The effects vary directly proportional to the used chemotherapy dose, the time period of exposure to the ascertained substances, and the general state of health of the patient, and the previous treatments for instance radiotherapy, immunotherapy. The toxic effects are known only as a result of the employed substance’s inhibition procedure on conjunct body organs. These phenomena limit the use of a few chemotherapy agents or better said, it is treated with caution, especially in patients with diminished renal function.

Do the sıde effects of antı-kıdney cancer therapy have a bad ımpact on renal functıons?

At about 50% of the patients, kidney cancer is identified at the first consultation of the patient to a urologist, through renal tumors (without symptoms). Specific to renal tumors are: hematuria, the presence of blood in the urine, backache, hemoptysis, pollakiuria (frequent emission of urine), abdominal mass, erythrocythemia (too many red blood cells in the blood). Other general symptoms can be: asthenia (feeling tired); perspiration especially during the night; dysplasia; severe weight loss.


      

    Share

    reklam ajansları